

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

NCT06493799

Status	RECRUITING
Phase	Phase 3
Sponsor	Green Cross Wellbeing
Enrollment	226 participants

Key Eligibility Criteria

Inclusion (4)

- At the time of screening, 19 or 70 years
- Those who have been diagnosed with alcoholic or non-alcoholic fatty liver disease
- Those who have increased ALT level (Increased ALT level : 60 IU/L d ALT d 200 IU/L)
- A person who can complete the signature agreement and comply with clinical trial requirements.

Exclusion (32)

- If you have the following disease
 - Liver cancer or other malignant tumor within 5 years at screening point
 - Esophageal varix bleeding, hepatic coma, ascites etc. related disease or Child-Pugh Score Class B,C patient within 1 year at screening point
 - Organs or bone marrow transplant experience
 - Billiary atresia, Genetic metabolic liver disease, Fulminant Hepatic failure, toxicity or Clinically diagnosed hepatitis, bleeding or Platelet disease patient
- ... and 27 more (see full listing online)

Locations (1 total)

GC wellbeing, Yongin-si, South Korea